Despite it being a week of considerable change, there was only one double-digit loser and one double-digit riser.
TLOU:Tlou Energy have shaken my trust quite badly, announcing a placing at 6p and causing an 18% drop in value. I'm very glad I sold half my holding a few weeks back. What adds insult to injury is that Australian investors are being invited to buy additional shares at 6p, but UK investors are not. I'm holding this share purely based on the track record of the directors, so when they do something like this it shakes my resolve to hold them.
The double-digit riser and Share of the Week for the second week in a row is IQE:IQE. This climbed 14% despite a scare on results day when the share plummeted, only to bounce back to a new high a few days later. Quite a few stop-losses were triggered so I'm glad I didn't have any! My ISA holding is now 102% up, with my more recent SIPP holding up by 26%. With a paper profit of £2,695 that consolidates it as Star Share. JLP:Jubilee Platinum disappointed this week, and dropped 5% so has a bit of catching up to do in 2nd place with £1,216 paper profit, and CAML:Central Asia Metals is still 3rd with £1,145.
OPTI:Optibiotix had an amazing week, climbing 6% and into profit for the first time ever. It now stands at £550 potential profit, slightly down from Thursday, but a whole lot better than 4 weeks ago when it had £1,400 loss. GVC:GVC Holdings climbed 6% too following superb results and a big special dividend. They are motoring towards 800p a share.
Here's the performance of the combined share and ISA accounts
| Weekly Change | |||
| Portfolio cost | £43,056.99 | +£0 | |
| Portfolio sell value (bid price - commission) | £41,188.83 | (-4.3%) | +£279.96 |
| Potential profits | £3,699.50 | +£421.41 | |
| Yr 2 Dividends | £357.10 | +£0 | |
| Yr 2 Profit from sales | £3,404.23 | +£0 | |
| Yr 2 Average monthly cash profit | £490.46 | -£15.33 | |
| Yr 2 Avg annual % of current portfolio cost | 13.7% | ||
| Total Dividends | £1,025.03 | +£0 | |
| Total Profit from sales | £7,244.49 | +£0 | |
| Average monthly cash profit | £417.17 | -£4.97 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 11.86% |
A quiet week with profits up £421 but some deepening losses wiping half of that out. Still well above 10% target for sales and dividends for both the year and overall.
A slight shallowing of the climb, but it is still a climb.
The SIPP looks like this after week 69
| Weekly Change | |||
| Portfolio cost | £16,776.69 | +£0 | |
| Portfolio sell value (bid price - commission) | £19,677.58 | (+17.3%) | +£165.31 |
| Potential profits | £3,471.94 | +£206.55 | |
| Yr 2 Dividends | £0 | +£0 | |
| Yr 2 Profit from sales | £842.07 | +£0 | |
| Yr 2 Average monthly cash profit | £207.51 | +£66.40 | |
| Yr 2 Avg annual % of current portfolio cost | 14.8% | ||
| Total Dividends | £413.19 | +£0 | |
| Total Profit from sales | £3,191.93 | +£0 | |
| Average monthly cash profit | £221.47 | -£3.25 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 15.8% |
A quiet week here too, and once more deepening losses take some of the gains away from the increased profits, largely thanks to CWR:Ceres Power and JLP:Jubilee Platinum dropping. The huge increase in year 2 performance is caused by a cock-up in my calculations over the last few months. I had this as week 26 of year 2, which is impossible if we're in week 69 overall. We're actually in week 17 of year 2, which makes the performance look a whole lot better. Oops!
The gap gets back to its widening ways
The trading account looks like this after week 35
| Weekly Change | |||
| Portfolio cost | £986.03 | +£0 | |
| Cash | £75.59 | +£0 | |
| Portfolio sell value (bid price - commission) | £801.41 | (-18.7%) | -£65.99 |
| Potential profits | £0 | +£0 | |
| Dividends | £0 | +£0 | |
| Profit from sales | £61.57 | +£0 | |
| Average monthly cash profit | £7.62 | -£0.23 | |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Avg annual % of current portfolio cost | 9.3% |
It's really been an unmitigated disaster has this account! I was expecting to be trading a share every couple of weeks, not every 6 months.
Yuck!
So, OPTI:Optibiotix is set to fly at last. SkinBioTherapeutics launches on 5th April and if Optibiotix shareholders get a chance to partake in the IPO I will be selling VEC:Vectura to free up £1,100 so I can join in. I'm also really hoping existing shareholders will get some free shares, as we own SkinBioTherapeutics now and are losing part of our company if we do not retain some share ownership.
JLP:Jubilee Platinum have released video of platinum concentrate being produced at Hernic, but there has been no RNS. That's surely got to be imminent and could propel Jubilee back to Star Share status.
AMYT:Amryt Pharma post results on Thursday, so we will be able to see if recent licensing deals are bringing in any revenue yet. There's a possibility of a significant re-rate if the news is good.
KIBO:Kibo Mining hinted that things were on track with the coal to power project in an RNS last week. I suspect nothing will happen next week, but the price is surely way too low at the moment. What could set things moving would be the announcement of the completion of the reverse takeover of OPRA:Opera Investments and the formation of Katoro Mining, particularly if that announcement mentions share distribution to existing holders.
It promises to be yet another exciting week...
No comments:
Post a Comment